Beam Therapeutics Reports First Clinical Results From BEAM-301 Trial
Shares climbed more than 4% on Tuesday after Beam Therapeutics released the first clinical results from its BEAM-301 trial. H.C. Wainwright said the results strengthen its conviction in the platform.
Shares of Beam Therapeutics (BEAM) climbed more than 4% on Tuesday after the company released the first clinical results from its BEAM-301 trial, which H.C. Wainwright said strengthens conviction in its platform.BEAM-301 is a one-time liver-targeted treatment designed to correct a common genetic er…